-
Jan 23, 2025 | 
radcliffecvrm.com | Faiez Zannad |Anish Gupta |Stephen Greene |Michelle M. Kittleson
Although cardio-kidney-metabolic disease (CKMD) incorporates conditions which share common risk factors, guidelines are often complex and vary between specialist groups. How can we achieve simpler CKMD guidelines to improve implementation? In this short interview, Dr Faiez Zannad (University of Lorraine, Nancy, FR) advocates for a single-set of overarching CKMD guidelines across all specialties.
-
Oct 4, 2024 | 
onlinelibrary.wiley.com | Nina Nouhravesh |Stephen Greene |Robert M. Clare |Daniel Wojdyla
Supporting Information Filename Description ejhf3458-sup-0001-Supinfo.docxWord 2007 document , 30.3 KB Appendix S1. Supporting Information. References 1, , , , , , et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
-
Sep 2, 2024 | 
hcplive.com | Muthiah Vaduganathan |Stephen Greene
00:00 - Welcome and Introduction01:18 - FINEARTS Study Design and Patient Population03:04 - Inclusion of Hospitalized Patients04:43 - Primary and Secondary Endpoints05:56 - Challenges in Achieving Statistical Significance07:39 - Health Status Improvement and Additional Analyses10:01 - Combination Therapy and Future Trials12:20 - Hyperkalemia and Steroidal vs.
-
Jun 14, 2024 | 
onlinelibrary.wiley.com | Antoni Bayes-Genis |Stephen Greene
Invited Editorial Bio-adrenomedullin: A weak biomarker for a STRONG patient Antoni Bayes-Genis, Corresponding Author Antoni Bayes-Genis Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Corresponding author. Department of Medicine, Head, Heart Institute, Hospital Universitari Germans Trias i Pujol, UAB, Carretera del Canyet s/n, 08916 Badalona, Spain. Email: [email protected] for more papers by this authorStephen J. Greene, Stephen J.
-
May 29, 2024 | 
hcplive.com | Muthiah Vaduganathan |Stephen Greene
May 29, 2024Brendon Neuen, MBBS, PhD, joins the podcast to discuss the latest updates in nephrology, including the landmark FLOW trial. The rise of semaglutide (Ozempic, Wegovy) is a phenomenon unlike any other witnessed in modern healthcare.
-
May 11, 2024 | 
onlinelibrary.wiley.com | Stephen Greene |Joseph B. Lerman |Josephine Harrington |RaKavius Chambers
Supporting Information Filename Description ejhf3199-sup-0001-Tables.docxWord 2007 document , 34.9 KB Appendix S1. Supporting Information. References 1, . Coronavirus disease 2019 (COVID-19) and the heart – Is heart failure the next chapter? JAMA Cardiol 2020; 5: 1216–1217. https://doi.org/10.1001/jamacardio.2020.3575 2, , , , , , et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19).
-
May 1, 2024 | 
spcare.bmj.com | Safi U. Khan |Muhammad Khan |Stephen Greene
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Apr 6, 2024 | 
hcplive.com | Muthiah Vaduganathan |Stephen Greene
0:00 - Intro 1:57 - Trial Design and Results 07:00 - Inclusion Criteria and Patient Characteristics 10:53 - Primary Results of EMPACT-MI 14:34 - Subgroup Analyses 15:27 - Implications for Post-MI Patient Population 19:53 - Take-home Messages for Care 23:39 - Kidney Outcomes in Post-MI Patient Population Heading into the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, few planned data releases garnered as much attention and anticipation as the EMPACT-MI trial offered...
-
Mar 26, 2024 | 
onlinelibrary.wiley.com | Tariq Jamal Siddiqi |Harriette Van Spall |Stephen Greene |Kainat Shariq
CONFLICT OF INTEREST STATEMENT Dr. Greene reported nonfinancial support from Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinentics, Merck, Novartis, and Pfizer; personal fees from Boehringer Ingelheim, Cytokinetics, AstraZeneca, Merck, Bayer, Roche Diagnostics, Vifor, Sanofi, Urovant Pharmaceuticals, and Bristol Myers Squibb; research support from the American Heart Association; grants from Novartis; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, and...
-
Feb 20, 2024 | 
onlinelibrary.wiley.com | Khawaja M Talha |James L. Januzzi |Stephen Greene |Muthiah Vaduganathan
Supporting Information Filename Description ejhf3165-sup-0001-Tables.docxWord 2007 document , 39.9 KB Table S1. Baseline characteristics for symptom analysis in patients with first diagnosis of heart failure. Table S2: Diasgnostic codes used for assessment clinical co-morbidities in heart failure patients included in this study. Table S3: Baseline characteristics of patients with incident heart failure diagnosis stratified by echocardiography testing status.
